Latest Global Markets News

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.

Australian Strategic Materials (ASM) has secured a $5 million federal grant to accelerate its Dubbo Project, progressing rare earth recovery innovations while navigating a complex global market landscape.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.

Clever Culture Systems Ltd has achieved a key cashflow break-even milestone in Q4 2024, driven by strong sales growth from major pharmaceutical clients including AstraZeneca and Bristol Myers Squibb. The company is also advancing its product line with a new APAS® Contact Plate capability set for mid-2025 launch.

Universal Biosensors is expanding its handheld testing portfolio with the upcoming AQUASCOUT water sensor and growing sales of its FDA-approved Xprecia Prime blood coagulation device, targeting multi-billion-dollar markets.

Black Rock Mining has cleared key regulatory hurdles for POSCO's US$40 million equity injection and secured US$179 million in debt facilities, setting the stage for construction of its Mahenge Graphite Project in Tanzania.

Fitzroy River Corporation's latest quarterly report reveals a dip in royalty income but highlights progress on major silver and gold projects, alongside strategic moves in energy royalties.

Bowen Coking Coal reported a strong December quarter with record coal sales and a 39% reduction in cash costs, underpinning a $29 million EBITDA despite softer coal prices.

Pureprofile Limited has upgraded its FY25 financial guidance following a robust first half, highlighted by a 22% revenue increase and a 30% surge in Q2, driven by strong international expansion and automation adoption.

Advanced Braking Technology Ltd (ASX: ABV) reported a robust 24% increase in product sales revenue for Q2 FY25, driven by international expansion and the launch of its innovative BrakeiQ system. The company’s underlying profit also grew by 25%, underscoring operational efficiencies and a strong global pipeline.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Talius Group reports a robust December quarter with $4.4 million revenue, positive operating cash flow, and a strategic $2.5 million capital raise, positioning the company for strong growth in 2025 amid evolving aged care legislation.